Corrigendum: Interleukin-2-Inducible T-Cell Kinase Deficiency-New Patients, New Insight?

Sujal Ghosh; Ingo Drexler; Sanil Bhatia; Heiko Adler; Andrew R Gennery; Arndt Borkhardt

doi:10.3389/fimmu.2018.02197

Corrigendum: Interleukin-2-Inducible T-Cell Kinase Deficiency-New Patients, New Insight?

Front Immunol. 2018 Oct 1:9:2197. doi: 10.3389/fimmu.2018.02197. eCollection 2018.

Authors

Sujal Ghosh¹, Ingo Drexler², Sanil Bhatia¹, Heiko Adler^{3

4

5}, Andrew R Gennery⁶, Arndt Borkhardt¹

Affiliations

¹ Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University, Düsseldorf, Germany.
² Institute for Virology, Medical Faculty, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
³ Research Unit Lung Repair and Regeneration, Comprehensive Pneumology Center, Helmholtz Zentrum München-Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Munich, Germany.
⁴ University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany.
⁵ German Center for Lung Research (DZL), Giessen, Germany.
⁶ Paediatric Immunology and HSCT, Newcastle University and Great North Children's Hospital, Newcastle upon Tyne, United Kingdom.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2018.00979.].

Keywords: Epstein–Barr virus-related malignancies; Interleukin-2-inducible T-cell kinase; combined immunodeficiency; lymphoproliferative disorders; primary immunodeficiency.

Publication types

Published Erratum